Early Response to Combination of Lamivudine and Interferon Alpha-2b in Patients with Posifive e Antigen of Chronic Hepatitis B
- VernacularTitle:拉米夫定联合?-2b干扰素治疗HBeAg阳性慢性乙型肝炎的早期应答
- Author:
Jiguang DING
;
- Publication Type:Journal Article
- Keywords:
Lamivudine;
Interferon ?-2b;
Chronic hepatitis B
- From:
Journal of Medical Research
2006;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the early efficacy and safety of combined sequential administration of lamivudine and interferon alfa-2b in patients with hepatitis Be antigen (HBeAg)-positive chronic hepatitis B. Methods 71 patients were divided into combined therapy growp (23 eases),interferon group (27 cases) and lamivudine group (21 cases).patients in the first group were given sequential combination treatment with of lamivudine monotherapy for nine weeks followed by lamivudine plus interferon alfa-2b for 15 weeks while patients in the interferon group and Lamivudine group received interferon alfa-2b monotherapy and lamivudine respectively. Results At 24weeks, 43.37% of the patients who received sequential combination treatment and 33.33% of those who received interferon alfa-2b monotherapy had HBeAg seroconversion,which is higher than those who received lamivudine monotherapy(9.52%, P0.05). The normolization rates of ALT in combining group , interferon group and Lamivudine group were 60.87%, 51.85% and 19.04% respectively(P
